Fig. 2.

hVEGF₁₆₅ and peptide 1 have similar binding properties whereas the activity of SS-deletion variants is reduced. (A) Peptide 1 strongly binds bevacizumab, and peptide 4 has intermediate bevacizumab binding capacities, whereas peptides 2, 3, 6, and 7 have virtually no binding capacities with bevacizumab. (B) hVEGF₁₆₅ and peptide 1 are equally well able to inhibit the binding of bevacizumab to plate-bound hVEGF₁₆₅ in a competition ELISA. (C) Peptides 1 and 4 are able to inhibit the binding of bevacizumab to hVEGF₁₆₅, whereas peptides 2 and 3 are not able to inhibit the binding of bevacizumab to hVEGF₁₆₅ in a competition ELISA. (D) Peptide 1 does not stimulate cell proliferation of VEGF dependent Ba/F3–VEGFR2 cells, nor does it affect the Ba/F3–VEGFR2 cell proliferation-promoting effects of hVEGF₁₆₅.